Education
About Us
Working with TipRanks
Follow Us
Scopus BioPharma (SCPS)
OTHER OTC:SCPS
Total Valuation
Scopus BioPharma has a market cap or net worth of $16.83K. The enterprise value is ―.
Market Cap$16.83K
Enterprise Value―
Share Statistics
Scopus BioPharma has 42,084,263 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,084,263
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Scopus BioPharma’s return on equity (ROE) is 1.77 and return on invested capital (ROIC) is 164.39%.
Return on Equity (ROE)1.77
Return on Assets (ROA)-29.60
Return on Invested Capital (ROIC)164.39%
Return on Capital Employed (ROCE)1.66
Revenue Per Employee0.00
Profits Per Employee-901.14K
Employee Count13
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Scopus BioPharma is ―. Scopus BioPharma’s PEG ratio is 0.00270.
PE Ratio―
PS Ratio0.00
PB Ratio-0.31
Price to Fair Value-0.31
Price to FCF-0.25
Price to Operating Cash Flow>-0.01
PEG Ratio0.00270
Income Statement
In the last 12 months, Scopus BioPharma had revenue of 0.00 and earned -11.61M in profits. Earnings per share was -0.55.
Revenue0.00
Gross Profit0.00
Operating Income-11.71M
Pretax Income-11.71M
Net Income-11.61M
EBITDA-11.71M
Earnings Per Share (EPS)-0.55
Cash Flow
In the last 12 months, operating cash flow was -3.04M and capital expenditures -1.55M, giving a free cash flow of -4.59M billion.
Operating Cash Flow-3.04M
Free Cash Flow-4.59M
Free Cash Flow per Share-0.11
Dividends & Yields
Scopus BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-107.36
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)2.18K
Important Dates
Scopus BioPharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Scopus BioPharma as a current ratio of 0.05, with Debt / Equity ratio of 0.00%
Current Ratio0.05
Quick Ratio0.05
Debt to Market Cap0.00
Net Debt to EBITDA0.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Scopus BioPharma has paid -105.05K in taxes.
Income Tax-105.05K
Effective Tax Rate<0.01
Enterprise Valuation
Scopus BioPharma EV to EBITDA ratio is -0.17, with an EV/FCF ratio of -0.24.
EV to Sales0.00
EV to EBITDA-0.17
EV to Free Cash Flow-0.24
EV to Operating Cash Flow-0.24
Balance Sheet
Scopus BioPharma has $362.10K in cash and marketable securities with $0.00 in debt, giving a net cash position of $362.10K billion.
Cash & Marketable Securities$362.10K
Total Debt$0.00
Net Cash$362.10K
Net Cash Per Share<$0.01
Tangible Book Value Per Share-$0.33
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Scopus BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―